Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Frontiers in Immunology Année : 2013

Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases?

Résumé

The TWEAK/Fn14 pathway is now well-known for its involvement in the modulation of inflammation in various human autoimmune/chronic inflammatory diseases (AICID) including lupus, rheumatoid arthritis, and multiple sclerosis. A panel of data is now available concerning TWEAK expression in tissues or biological fluids of patients suffering from AICID, suggesting that it could be a promising biological marker in these diseases. Evidences from several teams support the hypothesis that blocking TWEAK/Fn14 pathway is an attractive new therapeutic lead in such diseases and clinical trials with anti-TWEAK-blocking antibodies are in progress. In this mini-review we discuss the potential use of TWEAK quantification in AICD management in routine practice and highlight the challenge of standardizing data collection to better estimate the clinical utility of such a biological parameter.
Fichier principal
Vignette du fichier
fimmu-04-00489.pdf (438.7 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-01718196 , version 1 (18-04-2018)

Licence

Paternité

Identifiants

Citer

Daniel Bertin, Delphine Stephan, Michel Khrestchatisky, Sophie Desplat-Jégo. Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases?. Frontiers in Immunology, 2013, 4, pp.489. ⟨10.3389/fimmu.2013.00489⟩. ⟨hal-01718196⟩
139 Consultations
62 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More